Bristol-Myers Squibb’s study met its co-primary endpoint of overall survival with Opdivo® (nivolumab) plus low dose Yervoy® (ipilimumab) vs. chemotherapy in first-line Non-Small Cell Lung Cancer patients whose tumors expressed PD-L1 ≥1%. This is the third tumor type in which Opdivo plus Yervoy demonstrates overall survival benefit in a Phase 3 Trial. Learn more HERE
Read More
AstraZeneca’s trastuzumab deruxtecan was granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer.Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today. Learn more at:
Read More

LOS ANGELES, Calif., Oct. 2, 2019 – Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that the U.S. Food and Drug Administration (FDA) has approved a labeling supplement for NERLYNX® (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer. With the approval of the labeling supplement, the label now includes safety information based on interim results from Puma’s Phase II CONTROL Trial, a study evaluating antidiarrheal prophylaxis or dose escalation in the reduction of neratinib-associated diarrhea that has a primary endpoint of the incidence of grade 3 or higher diarrhea. Interim data from the trial showed that the addition of prophylactic treatment with loperamide plus budesomide reduced the discontinuation rate due to neratinib-associated diarrhea to 11% versus a discontinuation rate of 18% with loperamide alone. READ MORE

Read More
MINNEAPOLIS, MN- September 19, 2019 -The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia. The study is opening exclusively at the University of Minnesota Medical Center, and is being sponsored by GT Biopharma, Inc. Read More
Read More

Top-line analysis showed a highly statistically significant and clinically meaningful improvement in overall survival for CC-486

Celgene plans regulatory submissions beginning in 1H 2020

SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response (CR) or complete response with incomplete blood count recovery (CRi) with induction chemotherapy (with or without consolidation). The study demonstrated that maintenance treatment with CC-486 resulted in a highly statistically significant and clinically meaningful improvement in overall survival compared to placebo. The key secondary endpoint of relapse-free survival (RFS) also showed a statistically significant improvement. Read the full press release HERE.

Read More